[Clinicopathologic features of 234 cases with borderline ovarian tumors]
- PMID: 19570422
[Clinicopathologic features of 234 cases with borderline ovarian tumors]
Abstract
Objective: To determine the clinicopathologic characteristics and prognostic factors that may be used to predict the poor outcome of patients with borderline ovarian tumors.
Methods: All cases with borderline ovarian tumors treated in the West China Second University Hospital from January 2001 to June 2007 were analyzed retrospectively for clinicopathologic features, treatment parameters and outcome of treatment. Univariate and multivariate analyses were used to assess independent prognostic factors using the logistic regression model.
Results: The median age of 234 patients was 40.1 years with a range of 14 to 80 years. There were 101 (43.2%), 94 (40.2%), 19 (8.1%), 12 (5.1%), 8 (3.4%) cases of serous, mucinous, mixed, endometrioid and clear cell tumors, respectively. Out of 234 cases, 182 (77.8%) underwent laparotomy and 45 (19.2%) underwent laparoscopy. Seven women underwent laparoconversion. Fertility sparing surgery was performed on 119 cases (50.9%) and radical surgery was performed on 115 cases (49.1%). Totally 161 (68.8%) patients had stage I, 19 (8.1%) had stage II, 54 (23.1%) had stage III, and none had stage IV disease. Sixty-four women received postoperative chemotherapy. The median follow-up was 40 months with a range of 8 to 78 months. Recurrence was found in 26 cases (11.1%) during follow-up, and no tumor-related death was reported. The logistic regression model showed that surgery procedure (OR = 2.304, P = 0.024), cyst rupture (OR = 2.213, P = 0.038), stage (OR = 4.114, P < 0.01), microinvasion (OR = 2.291, P = 0.046) and peritoneal implants (OR = 2.101, P = 0.016) were the five independent prognostic factors affecting recurrence.
Conclusions: Although patients with borderline ovarian tumors have an excellent prognosis, the risk of recurrence remains in some patients. Emphasis should be put on these patients with high risk factors and preventive strategies should be taken to prevent their progression.
Similar articles
-
[Clinical and pathological features of borderline ovarian tumors].Zhonghua Fu Chan Ke Za Zhi. 2003 Feb;38(2):81-4. Zhonghua Fu Chan Ke Za Zhi. 2003. PMID: 12783693 Chinese.
-
Serous and mucinous borderline ovarian tumors: are there real differences between these two entities?Eur J Obstet Gynecol Reprod Biol. 2010 Dec;153(2):188-92. doi: 10.1016/j.ejogrb.2010.07.024. Epub 2010 Aug 21. Eur J Obstet Gynecol Reprod Biol. 2010. PMID: 20728981
-
[Clinical behavior of serous and mucinous borderline tumors of the ovary with diploid DNA stem line. Follow-up studies after organ preserving and non-organ preserving therapy].Zentralbl Gynakol. 2000;122(5):274-9. Zentralbl Gynakol. 2000. PMID: 10857214 German.
-
[Recent advances in studies of ovarian serous and mucinous borderline ovarien tumors].Zhonghua Bing Li Xue Za Zhi. 2006 Mar;35(3):173-5. Zhonghua Bing Li Xue Za Zhi. 2006. PMID: 16630508 Review. Chinese. No abstract available.
-
Histological classification of ovarian cancer.Med Electron Microsc. 2003 Mar;36(1):9-17. doi: 10.1007/s007950300002. Med Electron Microsc. 2003. PMID: 12658347 Review.
Cited by
-
Parameters of blood count and tumor markers in patients with borderline ovarian tumors: a retrospective analysis and relation to staging.ISRN Oncol. 2012;2012:947831. doi: 10.5402/2012/947831. Epub 2012 Apr 17. ISRN Oncol. 2012. PMID: 22577583 Free PMC article.
-
Fertility-sparing surgery for young patients with borderline ovarian tumors (BOTs): single institution experience.J Ovarian Res. 2016 Mar 18;9:16. doi: 10.1186/s13048-016-0226-y. J Ovarian Res. 2016. PMID: 26988551 Free PMC article.
-
Histologic distribution of borderline ovarian tumors worldwide: a systematic review.J Gynecol Oncol. 2013 Jan;24(1):44-51. doi: 10.3802/jgo.2013.24.1.44. Epub 2013 Jan 8. J Gynecol Oncol. 2013. PMID: 23346313 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical